OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacoeconomics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	366
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)	212
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	121
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018	121
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis	67
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study	57
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach	53
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers	53
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment	46
EQ-5D-Y Value Set for Slovenia	45
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	42
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers	42
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study	35
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice	34
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	33
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review	32
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension	31
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	30
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	29
Integrative Review of Managed Entry Agreements: Chances and Limitations	29
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	28
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine	26
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review	25
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden	24
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies	24

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	23
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	23
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States	22
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis	21
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis	21
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods	21
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups	21
Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering	20
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures	20
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review	19
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden	19
EQ-5D-Y Value Set for Germany	18
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates	18
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review	18
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA	17
Value Set for the EQ-5D-Y-3L in Hungary	17
A Comparison of PROPr and EQ-5D-5L Value Sets	17
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	17
Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer	17
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review	17
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma	16
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	16
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer	16
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	15
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic	15
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia	15
Modifying NICE’s Approach to Equity Weighting	15
A Value Set for the EQ-5D-Y-3L in the Netherlands	14
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	14
Economic Implications of Endometriosis: A Review	13
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	13
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	13
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine	13
Estimating an EQ-5D-Y-3L Value Set for China	13
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review	13
Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies	13
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US	13
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	13
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study	12
The Challenges of Measuring Informal Care Time: A Review of the Literature	12
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions	12
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management	11
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations	11
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China	11
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	11
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening	11
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	11
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve	11
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder	11
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	11

Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects	11
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer	11
Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation	11
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision	11
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review	10
The EQ-5D-5L Valuation Study in Egypt	10
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector	10
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest	10
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)	10
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness	10
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	9
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	9
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	9
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)	9
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review	9
Living Health Technology Assessment: Issues, Challenges and Opportunities	9
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review	9
Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers	8
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom	8
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	8
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review	8
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature	8
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers	8
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic	8
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	8
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	8
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland	8
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals	8
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	8
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden	8
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal	8
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	8
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets	8
Four Aspects Affecting Health Economic Decision Models and Their Validation	7
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	7
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	7
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada	7
Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome	7
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	7
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature	7
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA	7
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt	7
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	7
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	7
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies	7
Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods	7
Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development	7
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis	7
Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare	7
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups	7
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	7
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience	7
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review	7